Observational Study on the Use of Ivermectin as an Outpatient Treatment Option for COVID-19

• Conditions: COVID-19 Acute Bronchitis; COVID-19 Respiratory Infection; Covid19; COVID-19 Pneumonia
• Interventions: Drug: Ivermectin

• Registration Number: NCT05045937
• Lead Sponsor: Patrick Robinson

Brief Summary

Ivermectin is currently being utilized by a number of physicians in the local area. My objective will be to enroll these patients at the time of their evaluation for COVID-19 infection and to follow their progress through their recovery.

Detailed Description

Patients at local physician clinics as well as my own clinic will be enrolled at the time they are evaluated for having COVID-19. Patients enrollment will be voluntary and based upon their request for treatment with Ivermectin. These patients will be questioned on symptoms and the timing of those symptoms in detail. They will then be followed throughout their treatment course to evaluate their recovery experience. Detailed accounts of their symptoms and their resolution will be followed. The study patients will stop being followed when they are either admitted to the hospital or are deemed to be symptom free. Any other medications prescribed to the patients will also be tracked. Medical histories will be taken and documented to make comparisons at the end of the study. Those patients not requesting Ivermectin will also be followed for comparisons at a later date.

Study Timeline

• Study First Submitted: 2021-09-14
• Study First Submitted QC: 2021-09-14
• Study First Posted: 2021-09-16
• Status Verified: 2022-04
• Last Update Submitted: 2022-04-25
• Last Update Posted: 2022-04-27
• Study Start: 2022-05-01
• Primary Completion: 2024-05-01
• Study Completion: 2024-05-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

• Between the ages of 12-110 years old
• Has a recently completed COVID test
• Symptomatic and seeking treatment
• Willingness to participate and have follow-up
• Able and willing to take medications and treatment suggestions from the physician

Exclusion Criteria

Lack of symptoms, uncertain of COVID-19 status, outside of age limits for treatment

• No recent COVID test results
• Asymptomatic, even if COVID positive
• Outside of acceptable age range
• Meets criteria for hospital admission
• Unwilling to participate in trial study or have follow-up

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
COVID-19 patients treated with Ivermectin	Ivermectin	This group of patients will be those who requested to be treated with Ivermectin and whom have been prescribed such by different physicians. This group may or may not include those treated with Monoclonal Antibodies or Remdesivir.

Primary Outcome Measures

Name	Time	Method
Admission to a hospital for further advanced treatment	4-6 weeks per individual	This group of patients was unable to recover at home and required hospital admission
Complete recovery from COVID-19 with resolution of symptoms	4-6 weeks per individual	This group recovered completely from COVID-19 and remained an outpatient throughout the duration of their illness.

Trial Locations

Locations (1)

Patrick Robinson MD LLC; 🇺🇸 San Antonio, Florida, United States